Abstract
Adaptive Biotechnologies Corp will release first-quarter 2026 results on May 5, 2026 Post Market; this preview summarizes consensus expectations for revenue, margins, net loss trajectory, and adjusted EPS along with the most material segment drivers and prevailing analyst views since January 1, 2026 through April 28, 2026.
Market Forecast
Consensus for the current quarter anticipates total revenue of 60.85 million US dollars, an adjusted EPS of -0.16, and EBIT of -24.52 million US dollars; the year-over-year forecast implies revenue growth of 42.58% and adjusted EPS improvement of 45.30%, with EBIT improving 43.85%. No explicit gross margin or net margin guidance is available from consensus; based on the company’s historical profile, investors expect continued high gross efficiency, balanced by ongoing operating investment and a narrowed net loss.
The core business is projected to be led by minimal residual disease testing, with continued clinical adoption and enterprise contracts supporting growth momentum; the product and partnership portfolio in immune medicine offers an incremental contribution but remains smaller than services. The most promising segment is minimal residual disease services, expected to remain the principal revenue engine given its broad clinical footprint and expanding utilization across hematologic indications.
Last Quarter Review
In the previous quarter, Adaptive Biotechnologies Corp reported revenue of 71.68 million US dollars, a gross profit margin of 175.03%, a GAAP net loss attributable to the parent company of 13.58 million US dollars with a net profit margin of -18.94%, and adjusted EPS of -0.09, with year-over-year growth in revenue of 51.04% and adjusted EPS improvement of 60.87%.
The quarter exceeded consensus on all three tracked metrics: revenue, EPS, and EBIT, reflecting a stronger-than-expected top line and disciplined operating expense control. Main business highlights included minimal residual disease services revenue of 61.90 million US dollars and immune medicine revenue of 9.80 million US dollars, with the former accounting for the dominant share of quarterly sales and providing the key growth impulse on a year-over-year basis.
Current Quarter Outlook
Main business trajectory: minimal residual disease testing
Minimal residual disease services remain the lead indicator for near-term performance, anchoring the company’s revenue base and visibility. With consensus expecting company-wide revenue of 60.85 million US dollars in the quarter and forecasting a 42.58% year-over-year increase, market expectations imply sustained demand for testing volumes even against a tough comparison. Watch for commentary on testing mix, reimbursement stability, and account expansions, as these will influence realized average selling prices and throughput. The degree of operating leverage realized from this services scale-up will frame the path for adjusted EPS to improve toward the -0.16 forecast.
Most promising growth vector: scaling clinical adoption and enterprise deals
The largest upside lever this quarter is the breadth of clinical adoption and the cadence of enterprise agreements with health systems and biopharma partners tied to immune repertoire testing. As adoption deepens across hematologic malignancies and potentially adjacent indications, the revenue mix can benefit from both higher volume and premium-priced offerings. Investors will parse updates for evidence of contract wins and increased test utilization that could support the projected year-over-year revenue acceleration. Successful execution here would be consistent with consensus assumptions for EBIT improvement of 43.85% despite continued investment.
Key stock drivers this quarter: operating discipline and margin trajectory
Given the absence of explicit gross margin guidance, attention turns to operating expense control and the trajectory of the net loss. Last quarter’s upside on EBIT and adjusted EPS suggests that cost management is contributing alongside top-line growth, and investors will expect that pattern to extend. The critical swing factors are R&D prioritization, commercial efficiency, and cash operating runway; demonstration of incremental operating leverage could validate the expected adjusted EPS improvement of roughly 45% year over year. Any indication of stable to improving cash burn coupled with sustained high gross efficiency would likely be viewed favorably.
Analyst Opinions
Across recent commentary since January 1, 2026 through April 28, 2026, the dominant stance is cautiously bullish, emphasizing accelerating revenue momentum into the first quarter, improving operating leverage, and a line of sight to narrower losses. Analysts highlighting the setup point to a prior-quarter beat on revenue, EBIT, and adjusted EPS as supportive of the consensus path to 60.85 million US dollars in revenue and -0.16 in adjusted EPS. The prevailing view expects the minimal residual disease business to extend its lead, with sentiment hinging on confirmation of utilization growth and disciplined spending; under this framework, upside would come from stronger testing volumes or new agreements that outpace the already high 42.58% forecast growth rate.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments